In cancer, degradation of BRD9-induced downregulation of oncogenic transcriptional programs inhibited tumor progression in vivo only in a synovial subtype of sarcomas (and synovial sarcoma is concerned with stem cell malignancy) [156,157]. The gene discussed is BRD9; the disease is neoplasm.